Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.

Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

J Neurol Sci. 2019 Dec 15;407:116498. doi: 10.1016/j.jns.2019.116498. Epub 2019 Oct 15.

2.

Rituximab-induced serum sickness in multiple sclerosis patients.

Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E.

Mult Scler Relat Disord. 2019 Nov;36:101402. doi: 10.1016/j.msard.2019.101402. Epub 2019 Sep 17.

PMID:
31542710
3.

Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis.

Mowry EM, Corboy JR.

Lancet Neurol. 2019 Nov;18(11):983-985. doi: 10.1016/S1474-4422(19)30333-3. Epub 2019 Sep 3. No abstract available.

PMID:
31492653
4.

Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.

McGinley MP, Cola PA, Fox RJ, Cohen JA, Corboy JJ, Miller D.

Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314. [Epub ahead of print]

PMID:
31368401
5.

Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies.

Gross RH, Corboy JR.

Continuum (Minneap Minn). 2019 Jun;25(3):715-735. doi: 10.1212/CON.0000000000000738. Review. Erratum in: Continuum (Minneap Minn). 2019 Aug;25(4):1175.

PMID:
31162313
6.

Message from the Editors to our Reviewers.

Corboy JR, Powers LB, Anderson DC, Barbano RL.

Neurol Clin Pract. 2019 Apr;9(2):90-92. doi: 10.1212/CPJ.0000000000000616. No abstract available. Erratum in: Neurol Clin Pract. 2019 Jun;9(3):184.

PMID:
31041121
7.

Giving voice to patients.

Corboy JR.

Neurol Clin Pract. 2019 Feb;9(1):1. doi: 10.1212/CPJ.0000000000000592. No abstract available.

8.

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.

Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E.

Ann Clin Transl Neurol. 2018 Dec 9;6(2):252-262. doi: 10.1002/acn3.700. eCollection 2019 Feb.

9.

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE.

Biol Blood Marrow Transplant. 2019 May;25(5):845-854. doi: 10.1016/j.bbmt.2019.02.014. Epub 2019 Feb 19. Review.

10.

Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.

Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL.

Neurology. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11.

11.

Tools to address health care delivery challenges and improve patient outcomes.

Corboy JR.

Neurol Clin Pract. 2018 Dec;8(6):463. doi: 10.1212/CPJ.0000000000000565. No abstract available.

12.

Strength in numbers.

Corboy JR.

Neurol Clin Pract. 2018 Oct;8(5):363. doi: 10.1212/CPJ.0000000000000541. No abstract available.

13.

Adjustments in Torque Steadiness During Fatiguing Contractions Are Inversely Correlated With IQ in Persons With Multiple Sclerosis.

Gould JR, Reineberg AE, Cleland BT, Knoblauch KE, Clinton GK, Banich MT, Corboy JR, Enoka RM.

Front Physiol. 2018 Oct 17;9:1404. doi: 10.3389/fphys.2018.01404. eCollection 2018.

14.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487.

15.

Real-world practice.

Corboy JR.

Neurol Clin Pract. 2018 Aug;8(4):275. doi: 10.1212/CPJ.0000000000000501. No abstract available.

16.

Curbside consults join the telemedicine era.

Nuwer MR, Corboy JR.

Neurol Clin Pract. 2018 Jun;8(3):177-178. doi: 10.1212/CPJ.0000000000000459. No abstract available.

17.

Providing patient-centered care in the digital era.

Corboy JR.

Neurol Clin Pract. 2018 Jun;8(3):171. doi: 10.1212/CPJ.0000000000000474. No abstract available.

18.

The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.

Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E.

J Neurol Sci. 2018 Jul 15;390:89-93. doi: 10.1016/j.jns.2018.04.021. Epub 2018 Apr 13.

PMID:
29801915
19.

Partners in enhancing functional ability and well-being.

Corboy JR.

Neurol Clin Pract. 2018 Apr;8(2):83. doi: 10.1212/CPJ.0000000000000447. No abstract available.

20.

Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS.

Corboy JR, Weinshenker BG, Wingerchuk DM.

Neurology. 2018 Jun 12;90(24):1106-1112. doi: 10.1212/WNL.0000000000005574. Epub 2018 Apr 23. Review.

PMID:
29685920
21.

The physician as captain of the patient-centered ship.

Corboy JR.

Neurol Clin Pract. 2018 Feb;8(1):1. doi: 10.1212/CPJ.0000000000000427. No abstract available.

22.

Message from the Editors to our Reviewers.

Corboy JR, Powers LB, Anderson DC, Barbano RL.

Neurol Clin Pract. 2018 Feb;8(1):2-3. doi: 10.1212/CPJ.0000000000000428. No abstract available.

23.

Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.

Hassani A, Corboy JR, Al-Salam S, Khan G.

PLoS One. 2018 Feb 2;13(2):e0192109. doi: 10.1371/journal.pone.0192109. eCollection 2018.

24.

Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS).

Hebert JR, Corboy JR, Vollmer T, Forster JE, Schenkman M.

Neurology. 2018 Feb 27;90(9):e797-e807. doi: 10.1212/WNL.0000000000005013. Epub 2018 Jan 31.

PMID:
29386274
25.

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.

Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E.

Mult Scler J Exp Transl Clin. 2017 Aug 17;3(3):2055217317725102. doi: 10.1177/2055217317725102. eCollection 2017 Jul-Sep.

26.

The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Solomon AJ, Corboy JR.

Nat Rev Neurol. 2017 Sep;13(9):567-572. doi: 10.1038/nrneurol.2017.106. Epub 2017 Aug 11. Review. No abstract available.

PMID:
28799551
27.

Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - Commentary.

Corboy JR.

Mult Scler. 2017 Aug;23(9):1192-1193. doi: 10.1177/1352458517717809. Epub 2017 Jul 4. No abstract available.

PMID:
28673113
28.

Baló concentric sclerosis evolving from apparent tumefactive demyelination.

Hardy TA, Corboy JR, Weinshenker BG.

Neurology. 2017 May 30;88(22):2150-2152. doi: 10.1212/WNL.0000000000003990. Epub 2017 May 3. No abstract available. Erratum in: Neurology. 2017 Jul 25;89(4):411.

PMID:
28468846
29.

Author response: Reducing costs while enhancing quality of care in MS.

Kister I, Corboy J.

Neurology. 2017 Mar 21;88(12):1212. doi: 10.1212/WNL.0000000000003756. No abstract available.

PMID:
28320926
30.

Reducing costs while enhancing quality of care in MS.

Kister I, Corboy JR.

Neurology. 2016 Oct 11;87(15):1617-1622. Epub 2016 Sep 2.

31.

Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust.

Klein E, Solomon AJ, Corboy J, Bernat J.

Mult Scler Relat Disord. 2016 Jul;8:4-8. doi: 10.1016/j.msard.2016.04.001. Epub 2016 Apr 11.

PMID:
27456867
32.

Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS.

Neuro Oncol. 2016 Mar;18 Suppl 2:ii13-ii20. doi: 10.1093/neuonc/nov291. Review.

33.

Multiple sclerosis prevalence in the United States commercially insured population.

Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD.

Neurology. 2016 Mar 15;86(11):1014-21. doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.

34.

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R.

Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.

35.

Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.

Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA.

Mult Scler Relat Disord. 2014 Nov;3(6):696-704. doi: 10.1016/j.msard.2014.08.002. Epub 2014 Aug 29.

36.

Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates.

Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair K.

Mult Scler Relat Disord. 2014 Mar;3(2):227-36. doi: 10.1016/j.msard.2013.09.004. Epub 2013 Nov 2.

PMID:
25878010
37.

Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.

McQueen RB, Livingston T, Vollmer T, Corboy J, Buckley B, Allen RR, Nair K, Campbell JD.

J Manag Care Spec Pharm. 2015 Mar;21(3):210-8b.

38.

Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics.

Solomon AJ, Klein EP, Corboy JR, Bernat JL.

Mult Scler. 2015 Oct;21(12):1593-9. doi: 10.1177/1352458515569101. Epub 2015 Feb 25.

PMID:
25716879
39.

The effects of test-enhanced learning on long-term retention in AAN annual meeting courses.

Larsen DP, Butler AC, Aung WY, Corboy JR, Friedman DI, Sperling MR.

Neurology. 2015 Feb 17;84(7):748-54. doi: 10.1212/WNL.0000000000001264. Epub 2015 Jan 21.

40.
41.

Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells.

Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH Jr.

J Neuroimmunol. 2014 May 15;270(1-2):75-85. doi: 10.1016/j.jneuroim.2014.03.009. Epub 2014 Mar 15.

42.

Measuring family physician identity: the development of a new instrument.

Carney PA, Waller E, Eiff MP, Saultz JW, Jones S, Fogarty CT, Corboy JE, Green L.

Fam Med. 2013 Nov-Dec;45(10):708-18.

43.

Manipulating the nervous system: The brave new world.

Corboy JR.

Neurol Clin Pract. 2013 Dec;3(6):455-456. doi: 10.1212/01.CPJ.0000435750.40492.09. No abstract available.

44.

The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study.

Lafosse JM, Mitchell SM, Corboy JR, Filley CM.

J Int Neuropsychol Soc. 2013 Oct;19(9):995-1008. doi: 10.1017/S1355617713000957.

PMID:
24059259
45.

The American Academy of Neurology's top five Choosing Wisely recommendations.

Mattson DH, Lisak RP, Jones DE, Corboy JR, Larson R, Gronseth G, Getchius TS, Langer-Gould A, Langer-Gould AM, Gronseth GS, Larson R, Getchius TS.

Neurology. 2013 Sep 10;81(11):1022-3. doi: 10.1212/WNL.0b013e3182a69c98. No abstract available.

PMID:
24019388
46.

Persistent skin furuncle. Rapidly growing mycobacterial skin infection.

Corboy JE, Sarkar D, Goins WP.

Am Fam Physician. 2013 Sep 1;88(5):331-2. No abstract available.

47.

Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.

Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.

Am J Manag Care. 2013 Apr;19(4):278-85.

48.

The revolution of practice.

Corboy JR.

Neurol Clin Pract. 2013 Apr;3(2):87. doi: 10.1212/CPJ.0b013e31828e17fe. No abstract available.

49.

The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration.

Hebert JR, Corboy JR.

Gait Posture. 2013 May;38(1):37-42. doi: 10.1016/j.gaitpost.2012.10.015. Epub 2012 Nov 28.

PMID:
23200463
50.

Annual checkup.

Corboy JR.

Neurol Clin Pract. 2012 Dec;2(4):263-264. doi: 10.1212/CPJ.0b013e318278f3a2. No abstract available.

Supplemental Content

Loading ...
Support Center